Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-25
    E.g., 2018-06-25

Articles

172682 items
12:00 AM, Dec 20, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Molecular Biosystems regulatory update

Based on the letter and subsequent phone conversations with the FDA, MB said it does not believe that the questions threaten Albunex's approval. MB said it was encouraged by the relative emphasis in the letter...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Other News

University of Washington other research news

A transgenic mouse, which inappropriately expresses interleukin-4, develops a thinning of bone that resembles human osteoporosis, according to university scientists. The disease in the mice appears to result from decreased bone formation by the osteoblast...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Deals

Elan deal

ELN and Corange Ltd. signed an agreement to establish a 50-50 joint venture in Japan between ELN and Corange's Boehringer Mannheim KK subsidiary to develop and market certain of ELN's drug delivery products. The venture...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Deals

Metra deal

Metra's technology uses pyridinium crosslinks, which are markers specific to bone that are released into the blood and urine as a consequence of the bone resorption process. Metra's Pyrilinks and Pyrilinks D tests are sold...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Deals

Hemagen deal

HMGN entered into a renewable five-year agreement with Boehringer Mannheim GmbH to develop immunoassays using proprietary technology from both companies. The first test to be developed is an assay for Chagas, a parasitic disease believed...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Deals

Vertex deal

VRTX will develop orally active protease inhibitors to treat HIV and AIDS with Wellcome plc. Wellcome will pay up to $42 million to VRTX, $15 million of which will be an initial payment, as well...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Company News  |  Deals

Xoma Corp. deal

XOMA entered into a cross-licensing agreement with M.D. Anderson Cancer Center for technologies relating to recombinant DNA-derived gelonin, a ribosome-inactivating enzyme derived from seeds with potential for use in autoimmune treatments. XOMA received an...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Clinical News  |  Clinical Status

AM285: Began a Phase I study in 18 patients

Repligen Corp. (RGEN)   Product: AM285, small molecule which modulates energy metabolism in cells   Indication: Patients with late-stage malignant cancers that have not responded to prior therapy or for which there is no standard...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Clinical News  |  Clinical Status

APC 366: To begin a Phase I trial in the U.K. in January

Arris Pharmaceutical Corp. (ARRS)   Product: APC 366, small molecule that blocks mast cell-mediated inflammation   Indication: Asthma   Status: To begin a Phase I trial in the U.K. in January   ...
12:00 AM, Dec 20, 1993  |  BC Week In Review | Clinical News  |  Regulatory

Chiron regulatory update

CHIR also said its first Japanese patent application for HCV (No. 1-500565) was published for opposition on Nov. 15. The Japanese patent claims are related to proteins and immunoassays that incorporate antigenic fragments of the...

Pages